Tumores Mamários

Recomendações do consórcio de oncoplastia mamária para mastectomia e reconstrução mamária total em um cenário de radioterapia pós-mastectomia.

11 Abr, 2022 | 12:26h

Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy – The Breast

---

Estudo de coorte | Valor prognóstico de linfócitos infiltrativos no estroma em pacientes jovens com câncer de mama nódulo-negativo e triplo-negativo que não receberam terapia sistêmica (neo)adjuvante.

8 Abr, 2022 | 21:26h

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy – Journal of Clinical Oncology

 

Comentário no Twitter

Out now @JCO_ASCO huge effort of our team and @TILsWorkGroup: Excellent prognosis of TNBC pts with high TILs even without chemo! Chemo de-escalation trials urgently needed! # bcsm https://t.co/42eUZaA2vo

— MarleenKokLab (@lab_kok) March 31, 2022

 

---

M-A de estudos randomizados | Efeitos da capecitabina como parte da quimioterapia neo/adjuvante em pacientes com câncer de mama.

6 Abr, 2022 | 12:19h

Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients – European Journal of Cancer (link para o resumo – $ para o texto completo)

---

Comentário de estudo | Idosas com câncer de mama escolhem tratamentos menos agressivos quando usam ferramenta de auxílio à decisão.

1 Abr, 2022 | 12:40h

Older women with breast cancer chose less aggressive treatment when they used a decision aid – National Institute for Health Research

Estudo original: Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices – British Journal of Surgery

 

Comentário no Twitter

Open access in May's BJS: Bridging the age gap in breast cancer: two decision support interventions for older women with operable breast cancer https://t.co/s70uEVyAxU @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/IUuiUldUTS

— BJS (@BJSurgery) June 11, 2021

 

---

Estudo randomizado | Transtuzumab Deruxtecan vs. trastuzumabe Entansina para câncer de mama.

29 Mar, 2022 | 14:00h

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Trastuzumab Deruxtecan Ups PFS in HER2+ Metastatic Breast Cancer – HealthDay

 

Comentário no Twitter

In patients with metastatic HER2+ breast cancer that progressed after primary therapy, treatment with trastuzumab deruxtecan resulted in a higher response rate and longer progression-free survival than trastuzumab emtansine. https://t.co/R5suUeMLgE pic.twitter.com/yMiGrJw71U

— NEJM (@NEJM) March 24, 2022

 

---

Padrões longitudinais de longo prazo da fadiga relatada pelas pacientes após câncer de mama.

23 Mar, 2022 | 11:44h

Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis – Journal of Clinical Oncology

 

Comentário no Twitter

Congrats to @ines_vazluis, @dimeglio_anto & colleagues for another great publication from #CANTO! Here, they describe different patterns of fatigue developed after BC. Great to know that most pts (60%) fare well. We need to do better for those that don’t.https://t.co/VxxJvjECw9

— Paolo Tarantino (@PTarantinoMD) March 16, 2022

 

---

Incidência de recidiva de câncer de mama 10-32 anos após o primeiro diagnóstico.

23 Mar, 2022 | 11:34h

The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis – JNCI: Journal of the National Cancer Institute

---

M-A | Sobrevida após terapia neoadjuvante com trastuzumabe-lapatinibe e quimioterapia em pacientes com câncer de mama precoce HER-2-positivo.

16 Mar, 2022 | 17:16h

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials – ESMO Open

---

Estudo randomizado | Sobrevida geral do câncer de mama avançado com ribociclibe e letrozol.

11 Mar, 2022 | 14:56h

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentários:

Ribociclib plus endocrine therapy offers survival benefit for postmenopausal patients with metastatic breast cancer – University of Texas MD Anderson Cancer Center / News Medical

Adding Ribociclib to Letrozole Prolongs Survival in Advanced Breast Cancer – HealthDay

---

Mapeamento de revisões sistemáticas sobre intervenções na sobrevida do câncer de mama.

10 Mar, 2022 | 15:22h

Mapping Systematic Reviews of Breast Cancer Survivorship Interventions: A Network Analysis – Journal of Clinical Oncology

 

Comentário no Twitter

🌐 Despite vast volume, review-level #BreastCancer #survivorship research is unevenly distributed and siloed. Strategic planning of future research, in consultation with survivors, is needed. ➡️ https://t.co/pxMp5XK8B8 #JCO #BCSM @EmmaBKemp1 #survonc pic.twitter.com/TRjOEJQbrw

— Journal of Clinical Oncology (@JCO_ASCO) March 5, 2022

 

---